18:45 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Patient sample, cell culture and mouse studies suggest inhibiting CB1 could help treat Duchenne muscular dystrophy (DMD). In quadriceps tissue samples from pediatric DMD patients, CB1 expression levels were higher than in...
22:31 , Jan 6, 2017 |  BC Week In Review  |  Company News

Bird Rock, J&J deal

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Bird Rock to develop the biotech's namacizumab . The antibody targets cannabinoid CB1 receptor (CNR1) and is in Phase I testing in healthy volunteers...
00:57 , Jan 6, 2017 |  BC Extra  |  Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...